Cancer Expert MD

Few treatments in integrative oncology have had a more dramatic history than high-dose vitamin C. It was championed in the 1970s, dismissed in the 1980s after trials of oral vitamin C failed, and has returned in the last decade with a scientific explanation for both the early hopes and the early failures. The key is the route: vitamin C given into a vein reaches concentrations in the blood that are impossible to achieve by mouth, and at those concentrations it behaves like a different drug. This article explains how it works, what the randomized trials show, and the safety checks it requires.

Why the Route Changes Everything

The gut tightly limits how much vitamin C it absorbs. However much is swallowed, blood levels plateau at a low ceiling. Given intravenously, vitamin C bypasses that limit and reaches blood concentrations roughly 70 times higher than the maximum possible by mouth.¹ The failed trials of the 1980s used oral vitamin C, which never reached the levels that act on cancer cells. That is why their negative results do not apply to intravenous treatment.

How High-Dose Vitamin C Acts on Cancer Cells

It becomes a pro-oxidant around tumors. At normal levels vitamin C is an antioxidant. At the very high levels reached intravenously, it reacts in the fluid around cells to generate hydrogen peroxide. Researchers at the U.S. National Institutes of Health showed that this hydrogen peroxide selectively kills cancer cells, which handle it poorly, while normal cells, rich in the enzyme catalase, neutralize it.²

It targets KRAS- and BRAF-mutant cancers. Cancers driven by KRAS or BRAF mutations carry extra glucose transporters. A 2015 study in Science found that these cancer cells absorb the oxidized form of vitamin C through those transporters, which then shuts down a key enzyme in their sugar metabolism and kills them.³ KRAS mutations are found in most pancreatic cancers and many colorectal and lung cancers.

It works with chemotherapy and radiation. Laboratory and early clinical studies show high-dose vitamin C sensitizes cancer cells to chemotherapy and radiation while appearing to protect normal tissue from some of their damage.

What the Clinical Trials Show

Pancreatic cancer: survival doubled (2024)

At the University of Iowa, 34 patients with metastatic pancreatic cancer were randomly assigned to standard chemotherapy (gemcitabine and nab-paclitaxel) alone or with high-dose IV vitamin C three times a week. Median overall survival was 16 months with vitamin C compared with 8 months without it, and the trial was stopped early because the benefit was so clear. Patients receiving vitamin C also reported feeling better and could stay on chemotherapy longer.⁴ The same Iowa group has reported longer survival with vitamin C added to standard treatment in glioblastoma, and long-term survivors in an earlier trial combining vitamin C with radiation for pancreatic cancer.

The trial was small, and a larger trial is needed. The lead investigator has noted the obstacle: vitamin C cannot be patented, so no drug company has a reason to pay for the definitive phase 3 trial.

Colorectal cancer: the VITALITY trial (China)

The largest randomized trial, VITALITY, was run at Sun Yat-sen University Cancer Center in China. Patients with metastatic colorectal cancer received first-line FOLFOX chemotherapy, with or without bevacizumab, plus or minus high-dose IV vitamin C. Overall, vitamin C did not lengthen progression-free survival. But in patients whose cancers carried a RAS mutation, those receiving vitamin C did better, which fits the laboratory finding that KRAS-driven cancers are the most vulnerable.⁵ The lesson is the same one seen with many integrative treatments: the benefit depends on the biology of the specific cancer.

Quality of life during treatment (Germany)

In Germany, intravenous vitamin C is widely used alongside chemotherapy and radiation. A German multicenter study of women with breast cancer found that those who received complementary IV vitamin C reported fewer treatment-related complaints, such as nausea, loss of appetite and fatigue, than those who did not.⁶

Safety: The Checks Before the First Infusion

G6PD deficiency. People who lack the enzyme G6PD can suffer a dangerous breakdown of red blood cells (hemolysis) with high-dose vitamin C. A G6PD blood test is required before the first high-dose infusion. The deficiency is more common in people of African, Mediterranean, Middle Eastern and Asian descent.

Kidney function. Vitamin C is partly converted to oxalate, which can form kidney stones or damage kidneys that are already impaired. Kidney function is checked before treatment, and people with significant kidney disease or a history of oxalate stones need special caution.

Iron overload. Vitamin C increases iron absorption, a concern for people with hemochromatosis.

False blood sugar readings. High blood levels of vitamin C can make fingerstick glucose meters read falsely high for hours after an infusion. People with diabetes need to know this so they do not take insulin based on a false reading.

Fluid volume. Large infusions add fluid, which matters for people with heart failure.

Is Vitamin C an Antioxidant That Interferes with Chemotherapy?

This is one of the most common questions. At the very high levels reached intravenously, vitamin C acts as a pro-oxidant around cancer cells rather than shielding them. In the pancreatic cancer trial, it was given together with chemotherapy, and survival doubled rather than falling. Our book, The New Reality of Cancer, has a chapter devoted to antioxidants and intravenous vitamin C, including which antioxidants to avoid during treatment.

Frequently Asked Questions

Does high-dose vitamin C work for cancer?

In a 2024 randomized trial in metastatic pancreatic cancer, adding it to chemotherapy doubled median survival from 8 to 16 months. In a larger Chinese trial in colorectal cancer, it helped only patients with RAS-mutant tumors.

Is oral vitamin C the same as IV vitamin C?

No. The gut limits absorption, so oral vitamin C cannot reach the blood levels needed to act on cancer cells. Intravenous vitamin C reaches levels about 70 times higher.

What test is needed before IV vitamin C?

A G6PD test, because people with G6PD deficiency can develop dangerous hemolysis. Kidney function is also checked.

Which cancers respond best to vitamin C?

Laboratory and clinical evidence points to cancers with KRAS or BRAF mutations, including most pancreatic cancers and many colorectal cancers.

---

For more in-depth information on this topic and many others, get our book, The New Reality of Cancer: The Science of Recovery.

More articles on integrative cancer treatments, including hyperthermia, and all articles.

References

1. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Annals of Internal Medicine. 2004;140(7):533–537.
2. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proceedings of the National Academy of Sciences. 2005;102(38):13604–13609.
3. Yun J, Mullarky E, Lu C, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science. 2015;350(6266):1391–1396.
4. Bodeker KL, Smith BJ, Berg DJ, et al. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biology. November 2024.
5. Wang F, He MM, Xiao J, et al. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX ± bevacizumab versus FOLFOX ± bevacizumab in unresectable untreated metastatic colorectal cancer (VITALITY study). Clinical Cancer Research. 2022;28(19):4232–4239.
6. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25(6):983–990.

This article is for education only. It is not medical advice and does not diagnose or treat any condition. Cancer Expert MD has no financial relationship with any laboratory, drug maker, supplement company, clinic or hospital.